For more than twenty years, the conversation about menopause hormone therapy in the United States began with a warning label. Any woman who picked up a prescription for estrogen read a boxed warning — the strongest safety notice the FDA issues — referencing breast cancer, heart disease, and dementia. For many women, and a great many clinicians, that was where the conversation ended.

That changed. On November 10, 2025, the U.S. Department of Health and Human Services and the FDA announced they were initiating removal of those broad boxed warnings from menopausal hormone therapy products. On February 12, 2026, the FDA approved the first batch of updated labels — six products spanning every major category of hormone therapy — with the risk statements on cardiovascular disease, breast cancer, and probable dementia removed from the boxed warning.

If you are somewhere in the perimenopausal years and have been quietly managing hot flashes, broken sleep, brain fog, or changes you have not wanted to bring up, this is a reasonable moment to revisit the topic with a clinician. But a label change is not the same as a blanket recommendation, and the honest version of this story has more texture than the headlines. Below is that version — what changed, what did not, and how a careful evaluation actually works.

If you want the broader foundation first, our complete guide to hormone optimization in Tarzana covers hormone therapy for both men and women. This article focuses specifically on menopause and perimenopause.

The Short Version: What the FDA Changed in 2026

The FDA's action came after a review of the scientific literature, an expert panel convened in July 2025, and a public comment period. At the agency's request, 29 drug companies submitted proposed labeling changes. The first six approved products cover all four categories of menopausal hormone therapy: systemic combination therapy (estrogen plus a progestogen), systemic estrogen-alone therapy, systemic progestogen-alone therapy for women with a uterus who use systemic estrogen, and topical vaginal estrogen.

What was removed

Three risk statements came out of the boxed warning: cardiovascular disease, breast cancer, and probable dementia. The FDA also stated that its labeled recommendation will be to begin systemic hormone therapy within 10 years of menopause onset, or before age 60.

What stayed

This part matters and is frequently left out of coverage. The FDA is not removing the boxed warning for endometrial cancer from systemic estrogen-alone products. That warning is the reason women who still have a uterus and use systemic estrogen are also prescribed a progestogen — it protects the lining of the uterus. Removing a warning from a label also does not mean a medication carries no risk; it means the agency concluded the boxed warning was not the right place for those particular statements.

Why the Warnings Were There in the First Place

The boxed warnings were added in the early 2000s following the Women's Health Initiative (WHI), a large trial whose findings reshaped prescribing almost overnight. Two details about that trial are central to the FDA's re-evaluation: the average age of participants was 63 — more than a decade past the typical age of menopause — and the hormone formulation studied is no longer in common use.

In other words, a trial largely conducted in women well past the menopause transition became the basis for warnings applied to every woman considering hormone therapy, including a 49-year-old with disruptive hot flashes. The FDA's position is that this produced a distorted picture of risk. The agency notes that in 2020 roughly 41 million U.S. women were between 45 and 64, while only about 2 million women aged 46 to 65 received a hormone therapy prescription.

What the Menopause Society Says — and Why Nuance Still Matters

Professional societies responded on the same day, and their response is worth reading carefully because it is more measured than the press conference.

The Menopause Society agreed with removing the boxed warning from low-dose vaginal estrogen, noting that the warning likely deterred women from using a safe and effective therapy for a condition affecting most menopausal women. On systemic estrogen, the Society was more reserved: systemic estrogen still carries potential risks in certain individuals that should be reviewed in detail before starting therapy. Per its hormone therapy position statement, risks are low for younger, healthy women starting closer to the menopause transition, and greater for older women and those further from menopause onset. Medical comorbidities, personal and family history, symptoms, and personal preference all belong in the discussion.

That is the practical takeaway. Hormone therapy became easier to discuss in 2026. It did not become a one-size-fits-all prescription, and it is not appropriate for everyone.

Perimenopause vs. Menopause: Knowing Where You Are

Menopause itself is a single point in time — twelve consecutive months without a menstrual period. Perimenopause is the transition leading up to it, and it is where most of the symptom burden lives. Cycles become unpredictable. Estrogen does not decline in a tidy line; it fluctuates, sometimes dramatically, which is precisely why this stage can feel so destabilizing.

Duration is often underestimated. In the Study of Women's Health Across the Nation (SWAN), a long-running multiracial, multiethnic study of the menopause transition, the median total duration of frequent hot flashes and night sweats was 7.4 years, with a median persistence of 4.5 years after the final menstrual period. Women who began having frequent vasomotor symptoms while still premenopausal or in early perimenopause had the longest course — a median exceeding 11.8 years. This is not, for many women, a short phase to wait out.

Why a single hormone test often is not the answer

A common frustration: a woman with textbook perimenopausal symptoms has bloodwork drawn, is told her hormones are "normal," and leaves without a plan. The explanation is straightforward. During perimenopause, FSH and estradiol fluctuate day to day, so a single measurement is an unreliable indicator of where someone is in the transition. In otherwise healthy women over 45, perimenopause and menopause are generally diagnosed clinically — from the pattern of vasomotor symptoms, irregular cycles, and absence of periods — rather than from a lab value.

What lab work is actually useful

Testing still has a real role; it is simply a different one. Rather than trying to confirm a diagnosis that the symptom history already makes clear, thoughtful comprehensive lab testing is used to establish a baseline, look for conditions that mimic or compound menopausal symptoms — thyroid dysfunction and iron deficiency are classic examples — and assess cardiometabolic and bone-health context that belongs in any hormone therapy decision. Our guide to diagnostic bloodwork and hormone panels walks through what these panels typically include and how results are interpreted alongside symptoms.

Symptoms That Deserve a Real Conversation

Hot flashes and night sweats are the recognizable ones, but they are far from the whole picture. Symptoms commonly reported across the transition include:

• Vasomotor symptoms — hot flashes, night sweats, and the sleep disruption they cause
• Sleep changes independent of night sweats, including early-morning waking
• Mood shifts, irritability, heightened anxiety, or a flatness that feels unfamiliar
• Difficulty with word recall, focus, and short-term memory
• Vaginal dryness, discomfort with intimacy, and urinary changes — often grouped as genitourinary symptoms of menopause
• Joint aches and new stiffness
• Shifts in body composition, particularly loss of lean muscle and redistribution of fat toward the midsection
• Accelerated bone loss, which raises fracture risk over time

The last two are worth naming clearly because they are frequently dismissed as inevitable. Muscle and bone are estrogen-responsive tissues, and changes there are measurable rather than imagined. An InBody body composition analysis gives an objective baseline for lean mass and body fat distribution, which is far more informative than tracking scale weight through a transition where body composition can shift while weight holds steady. Our guide to body composition analysis explains what those numbers do and do not tell you.

The Main Categories of Menopause Hormone Therapy

"HRT" is a broad term covering meaningfully different treatments with different risk profiles and different jobs. Which one is appropriate depends on your symptoms, your medical history, and whether you have a uterus. All of the below require a prescription and clinical supervision.

Systemic estrogen

Delivered as a patch, gel, spray, or oral tablet, systemic estrogen treats symptoms that travel through the whole body — hot flashes, night sweats, and the sleep disruption that follows — and is FDA-approved for preventing bone loss. Route of delivery is not a trivial detail; it is one of the things a clinician weighs against your personal and family history.

A progestogen for uterine protection

If you have a uterus and use systemic estrogen, a progestogen is added to protect the endometrium. This is the clinical response to the endometrial cancer warning that the FDA specifically retained.

Low-dose vaginal estrogen

This is a local therapy for genitourinary symptoms — dryness, discomfort, irritation, and some urinary changes. It is the category the Menopause Society singled out as safe and effective for a very common problem, and where it agreed the boxed warning had been a deterrent. Women who cannot or do not want to use systemic hormones may still be candidates for local therapy; that is a conversation worth having rather than assuming.

What About "Bioidentical" and Compounded Hormones?

The word "bioidentical" gets used two different ways, and conflating them causes real confusion.

Many FDA-approved products contain hormones structurally identical to those the body produces — estradiol and micronized progesterone among them. These are regulated, tested for potency and purity, and carry a label outlining risks.

Custom-compounded "bioidentical" preparations are a different matter. The Menopause Society's 2022 hormone therapy position statement is direct: compounded bioidentical hormone therapy presents safety concerns and is not recommended. The cited concerns include minimal government regulation and monitoring, the potential for overdosing or underdosing, impurities or lack of sterility, absence of scientific efficacy and safety data, and no label outlining risks. Narrow exceptions exist — an allergy to an ingredient in an approved formulation, or a dose not available in an approved product — but those are specific clinical situations, not a general preference.

If a provider is promoting compounded pellets or creams as safer or more "natural" than FDA-approved therapy, that claim is not supported by the position statements of the major menopause societies. It is a fair question to ask directly.

Non-Hormonal Options for Hot Flashes

Some women have a medical history that makes systemic hormones inadvisable. Others simply prefer not to use them. Both are legitimate, and the options have genuinely improved.

In October 2025, the FDA approved elinzanetant (brand name Lynkuet), a dual neurokinin 1 and neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms due to menopause. Rather than replacing hormones, it acts on the brain's thermoregulatory signaling. Approval was supported by the phase 3 OASIS trial program; in OASIS-3, elinzanetant reduced the frequency of moderate-to-severe vasomotor symptoms by more than 73% at 12 weeks, compared with 47% for placebo. The FDA's November 2025 announcement also included the first generic conjugated estrogens approval in more than 30 years, which speaks to access rather than mechanism.

Whether any specific medication is appropriate for you — hormonal or not — depends on your history and is a prescribing decision for your clinician.

The Timing Question: Is There Really a Window?

The FDA's stated labeled recommendation is to begin systemic hormone therapy within 10 years of menopause onset or before age 60, and the agency points to randomized data showing reductions in all-cause mortality and fractures among women who start within that window. The Menopause Society frames the same evidence from the risk side: risks are low for younger, healthy women starting near the transition and greater for those starting later and further out.

Both statements point in the same practical direction. Timing genuinely matters, which is an argument for having the conversation earlier rather than filing it away for later. It is not, however, a reason to start a medication you have not had properly evaluated, and being outside that window does not automatically rule out every option — including local vaginal estrogen and non-hormonal therapies.

What a Careful Evaluation Looks Like

At Contour Medical Clinic in Tarzana, hormone-related care begins with a conversation rather than a protocol. A thorough evaluation generally includes:

• A detailed symptom and cycle history — what you are experiencing, how long it has been going on, and what it is costing you day to day
• Personal and family medical history, including cardiovascular, clotting, and cancer history, which shapes whether and how systemic therapy is appropriate
• Baseline diagnostics through comprehensive lab testing, used to rule out mimicking conditions and establish cardiometabolic context
• Objective body composition analysis so that changes in lean mass are tracked rather than guessed at
• An honest discussion of options — systemic hormone therapy, local vaginal estrogen, non-hormonal prescription options, and non-pharmacologic support — including the ones we would not recommend for you
• A follow-up plan, because dose, route, and tolerability are refined over time rather than settled at the first visit

You can read more about our approach to hormone therapy in Tarzana, which covers care for both women and men. If you are researching on behalf of a partner, our article on TRT and the 2026 testosterone guidelines covers the male side of that conversation.

Where Recovery, Strength, and Longevity Fit In

Hormone therapy is one input among several, and the surrounding habits are not decoration. Resistance training and adequate protein remain the most reliable defense against the loss of lean muscle during and after the transition. Sleep quality is both a symptom and a lever. Cardiometabolic health becomes more consequential after menopause, not less.

This is where the rest of Club Contour Studios fits naturally into a plan. Many members use the Wellness Lounge for recovery and stress regulation — infrared sauna sessions for warmth and relaxation, cold plunge for post-training recovery, or contrast therapy combining the two. If skin firmness and body contour are part of what you want to address, Venus Legacy treatments in the Contour Lounge are non-invasive and complement, rather than substitute for, medical care. For a longer-horizon view of biological aging and healthspan, our longevity medicine program and the accompanying healthspan and biological age guide go deeper. And when metabolic health is the more pressing concern, physician-supervised medical weight loss may be the better starting point.

Frequently Asked Questions

Does the FDA label change mean hormone therapy is now considered safe for everyone?

No. The FDA removed specific risk statements from the boxed warning after concluding they were not well supported by current evidence for the women most likely to benefit. Individual risk still depends on your age, how long it has been since menopause onset, your medical history, and the specific therapy. The Menopause Society continues to advise a detailed individual risk review before starting systemic estrogen.

Is the endometrial cancer warning still on the label?

Yes. The FDA specifically stated it is not seeking removal of the boxed warning for endometrial cancer on systemic estrogen-alone products. This is why women with a uterus who use systemic estrogen are also prescribed a progestogen.

Can I be treated during perimenopause, or do I have to wait until periods stop?

Perimenopausal symptoms are treatable, and waiting is not a requirement. Because cycles are still occurring and hormone levels fluctuate, the approach in perimenopause differs from post-menopausal care — which is exactly why it warrants an individual evaluation rather than a standard protocol.

Do I need a blood test to confirm perimenopause?

Usually not for diagnosis. In healthy women over 45, perimenopause and menopause are typically diagnosed from symptoms and cycle changes, because a single FSH or estradiol measurement is unreliable when levels fluctuate. Lab work is still valuable for ruling out other causes and establishing a baseline.

Are compounded bioidentical pellets a better option?

The Menopause Society's 2022 position statement does not recommend compounded bioidentical hormone therapy, citing limited regulation and monitoring, dosing accuracy concerns, potential impurities, and the absence of efficacy and safety data and risk labeling. FDA-approved products that contain body-identical hormones such as estradiol and micronized progesterone are available and regulated.

What if I cannot or do not want to use hormones?

Non-hormonal prescription options for moderate-to-severe hot flashes exist, including the neurokinin-targeted therapy approved in October 2025. Low-dose vaginal estrogen is also a separate consideration from systemic therapy for genitourinary symptoms. Which options apply to you is a clinical decision made with your provider.

Schedule a Consultation in Tarzana

If you have been managing symptoms alone, or were told years ago that hormone therapy was off the table without much discussion, the landscape has changed enough to warrant a fresh conversation. What has not changed is that the decision should be individual, evidence-based, and made with a clinician who will explain the reasoning — including the reasons a particular therapy might not be right for you.

Contour Medical Clinic is located inside Club Contour Studios at 19327 Ventura Blvd #F in Tarzana, serving Encino, Woodland Hills, Sherman Oaks, and the surrounding San Fernando Valley. Request a medical consultation to discuss perimenopause and menopause care, or call (818) 835-5081 with questions.

This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. Hormone therapy requires evaluation and prescription by a qualified clinician. Individual results and eligibility vary. Nothing here should be used to start, stop, or change a medication without speaking with your own provider.

Written by: Contour Medical Clinic Editorial Team